MacroGenics MGNX 深 沪
已收盘 12-12 16:00:00 美东时间
1.40
-0.010
-0.71%
华盛通- 最 高1.45
- 今 开1.44
- 成交量 66.25万股
- 最 低 1.38
- 昨 收 1.41
- 总市值 8848.80万
- 52周最高 3.60
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 0.9897
- 委 比 -61.20%
- 总股本 6320.57万
- 历史最高 41.00
- 量 比 0.28
- 振 幅 4.96%
- 历史最低 0.9897
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
MacroGenics, Inc. announced that its President and CEO, Eric Risser, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4 at 7:55 am ET in Miami, FL. The presentation will be available via webcast under "Events & Presentations" on MacroGenics' Investor Relations website, with an archived replay for 30 days.
11-25 21:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.58) by 146.31 percent. This is a 70 percent decrease over earnings of $0.90 per share from the
11-13 05:41
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
<p>MacroGenics首席执行官Eric Risser将参加Stifel 2025医疗健康大会炉边谈话。活动时间为2025年11月13日纽约下午4点。网络直播及其存档可在公司投资者关系页面访问。</p>
11-06 21:30
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.
11-03 20:02
Mawson Infrastructure Group, Inc. Releases Preliminary Estimated Results for Third Quarter and Nine Months Ended September 30, 2025
Mawson Infrastructure Group Inc. has announced preliminary financial results for Q3 and 9 months ended September 2025, showing a 9% YoY revenue decrease to $11.2M but a 53% gross profit increase to $6.6M. Gross margin improved from 35% to 59%. For 9 months, revenue dropped 22% to $34.5M, but gross profit rose 5% to $16.4M with a 48% margin. Net loss reduced 76% to $9.8M. The Company also announced results of its 2025 Annual Shareholder Meeting, e...
10-17 10:00
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
MacroGenics, Inc. announced that CEO Eric Risser will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:30am ET in New York. A webcast will be available under "Events & Presentations" on the Company's website, with a 30-day replay. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer, utilizing proprietary technology platforms and collaborating with global pharmaceut...
09-02 20:30
MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors?
MacroGenics Inc (($MGNX)) announced an update on their ongoing clinical study. ...
08-15 00:27
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
MacroGenics reported Q2 2025 financial results with a cash position of $176.5M, up from $134.9M in Q2 2024, and highlighted strategic priorities for lorigerlimab, MGC026/MGC028 advancement, IND submissions, and partnerships. Notably, they received a $70M upfront payment from Sagard for ZYNYZ and aim to enhance operational efficiency to improve financial position.
08-14 20:01
